GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis
GLP-1-Rezeptoragonisten-Therapie und kardiorenale Outcomes bei Typ-1-Diabetes: Propensity-gematchte Real-World-Analyse
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6347-6357
DOI: 10.1111/dom.70841 ↗Auf einen Blick
Bei Erwachsenen mit Typ-1-Diabetes war eine GLP-1-basierte Therapie in dieser Real-World-Kohorte mit geringeren Risiken für Mortalität, Herzinsuffizienz, MACE, Hospitalisation und Hypoglykämie verbunden. Das DKA-Risiko war nicht erhöht.
Fragestellung
Welche kardiorenalen Wirksamkeits- und Sicherheitsoutcomes sind bei Erwachsenen mit Typ-1-Diabetes unter GLP-1-basierter Therapie im Vergleich ohne diese Therapie beobachtbar?
Methode
Retrospektive Kohortenstudie in TriNetX mit 1:1-Propensity-Matching; Ereignisse ab 6 Monaten nach Therapiebeginn; Vergleich von Erwachsenen mit Typ-1-Diabetes mit und ohne GLP-1-basierte Therapie.
Ergebnisse
Nach Matching waren 4088 Personen pro Gruppe eingeschlossen. Niedrigeres Risiko für Gesamtmortalität (HR 0,67; 95 %-KI 0,46–0,98), Herzinsuffizienz (HR 0,38; 95 %-KI 0,21–0,67), adaptierte MACE (HR 0,61; 95 %-KI 0,40–0,94), Hospitalisation (HR 0,70; 95 %-KI 0,51–0,96) und Hypoglykämie (HR 0,72; 95 %-KI 0,55–0,95).
Schlussfolgerung der Autor:innen
In dieser gematchten Real-World-Kohorte war GLP-1-basierte Therapie mit niedrigeren Risiken für mehrere klinische Outcomes und ohne erhöhtes DKA-Risiko assoziiert. Randomisierte kontrollierte Studien sind zur Bestätigung erforderlich.
Kernaussagen
- Gesamtmortalität, HF, MACE und Hospitalisation waren seltener unter GLP-1-Therapie.
- Hypoglykämie war unter GLP-1-Therapie seltener; DKA nahm nicht zu.
- Myokardinfarkt, ischämischer Schlaganfall und CKD unterschieden sich nicht signifikant.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Journal article in Diabetes, Obesity and Metabolism, published online on 2026-05-06. Written by Anastasios Tentolouris and 7 co-authors. Institution: First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, Laiko General Hospital, National and Kapodistrian Univers…. Major MEDLINE topics: Diabetes Mellitus, Type 1, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Cardiovascular Diseases. Cited 4 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Aims
Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort. Materials and Methods This retrospective cohort study utilised the TriNetX global health research network. Adults with T1D were classified by exposure to GLP‐1‐based therapies. Propensity score matching (1:1) balanced baseline characteristics for age, sex, demographic characteristics, cardiometabolic risk factors, comorbidities, medication use, and laboratory parameters including lipid profile and glycemic control. Outcomes included all‐cause mortality, myocardial infarction, cerebral infarction, heart failure (HF), adapted major adverse cardiovascular events (MACE—all CV clinical outcomes), chronic kidney disease (CKD), and all‐cause hospitalisation, plus safety outcomes (hypoglycemia and DKA). Event accrual began 6 months after therapy initiation.
Results
After matching, 4088 individuals per group were included. GLP‐1‐based therapy was associated with lower risks of all‐cause mortality (HR 0.67, 95% CI 0.46–0.98), HF (HR 0.38, 95% CI 0.21–0.67), adapted‐MACE (HR 0.61, 95% CI 0.40–0.94) and all‐cause hospitalisation (HR 0.70, 95% CI 0.51–0.96). No significant differences were observed for myocardial infarction, ischemic stroke, or CKD. DKA incidence was not increased, while hypoglycemia risk was lower with GLP‐1 therapy (HR 0.72, 95% CI 0.55–0.95). Less than 10 (0.2%) events of pancreatitis were noted in both groups.
Conclusions
In this propensity score‐matched real‐world cohort of adults with T1D, GLP‐1‐based therapy was associated with lower risks of all‐cause mortality, HF, adapted‐MACE, hospitalisation, and hypoglycemia without increased DKA risk. Randomised controlled trials are needed to confirm these findings.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Internal Medicine, School of Medicine, University of Crete, Crete, Greece.
ORCID profiles: Anastasios Tentolouris, Nikolaos-Iason Tepetes, Alexandros Briasoulis
Cite
APA
Tentolouris, A., Filippatos, C., Tepetes, N. I., Gavriatopoulou, M., Terpos, E., Briasoulis, A., Stamatelopoulos, K., & Filippatos, T. (2026). GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis. Diabetes, Obesity and Metabolism, 28(7), 6347-6357. https://doi.org/10.1111/dom.70841
Vancouver
Tentolouris A, Filippatos C, Tepetes NI, Gavriatopoulou M, Terpos E, Briasoulis A, et al. GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis. Diabetes, Obesity and Metabolism. 2026;28(7):6347-6357. doi:10.1111/dom.70841
BibTeX
@article{Tentolouris2026,
author = {Tentolouris, Anastasios and Filippatos, Charalampos and Tepetes, Nikolaos-Iason and Gavriatopoulou, Maria and Terpos, Evangelos and Briasoulis, Alexandros and Stamatelopoulos, Kimon and Filippatos, Theodosios},
title = {GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {6347--6357},
doi = {10.1111/dom.70841}
}
EUVIMED